Galassi, Claudia
Galluzzi, Lorenzo http://orcid.org/0000-0003-2257-8500
Article History
Received: 4 July 2023
Revised: 10 August 2023
Accepted: 16 August 2023
First Online: 21 August 2023
Competing interests
: CG has no conflicts of interest to declare. LG is/has been holding research contracts with Lytix Biopharma, Promontory and Onxeo, has received consulting/advisory honoraria from Boehringer Ingelheim, AstraZeneca, OmniSEQ, Onxeo, The Longevity Labs, Inzen, Imvax, Sotio, Promontory, Noxopharm, EduCom, and the Luke Heller TECPR2 Foundation, and holds Promontory stock options.